Rheumatology

Investigators Review Marketed Adalimumab Biosimilars for Switching Differences

October 16th 2021

By Deana Ferreri, PhD

Investigators in Spain said they found no significant differences in outcomes for patients who switched from adalimumab originator to 1 of multiple adalimumab biosimilars.

FDA Grants Interchangeable Status for Boehringer Ingelheim's Adalimumab Biosimilar (Cyltezo)

October 15th 2021

By Tony Hagen

The interchangeable designation allows pharmacists more flexibility to dispense this potentially money-saving product and gives Boehringer Ingelheim a marketing edge.

Dose Adjustment, Infusion Interval Changes Hold Value for Patients With AS Treated With CT-P13

October 14th 2021

By Tony Hagen

Investigators said the RAAS study filled in missing information on the value of dose modulations and infusion interval changes for patients with ankylosing spondylitis (AS) treated with CT-P13 (Remsima, Inflectra).

Biosimilars Forum Launches State-by-State Savings Calculator

October 13th 2021

By Tony Hagen

An interactive tool from Biosimilars Forum, an industry group, uses data from Pacific Research Institute to calculate potential biosimilar savings based on 75% market share.

Polpharma Biologics Executives Discuss Ranibizumab Biosimilar and Other Product Candidates

October 13th 2021

The Center for Biosimilars® speaks with Polpharma Biologics executives Alex Moulson, vice president of Development, and Pawel Lewinski, head of Portfolio and Commercial Strategy, about the company's biosimilar pipeline.

Court Dismisses AbbVie's Trade Secret Piracy Case Against Alvotech

October 7th 2021

By Tony Hagen

A US District Court in Illinois has ruled that although trade secret theft may have occurred over an adalimumab biosimilar candidate, it happened far from the state. With only a very "attenuated" connection, there are no grounds to bring action against Alvotech in the case of purloined manufacturing data, the judge stated.

Twelve-Month Court Battle Will Delay Adalimumab Biosimilar Launch for Alvotech

October 6th 2021

By Tony Hagen

The court battle between AbbVie and Alvotech could be a defining victory in the struggle to bring biosimilar versions of adalimumab to market, but a yearlong court process must play out first.

Canadian Experts Offer Switching Guidance for Biosimilars in Rheumatology

October 5th 2021

By Tony Hagen

Preventing the nocebo effect requires a demonstration of confidence in biosimilars from all health care practitioners, including pharmacists, experts said in a newly published rheumatology treatment guidance document.

Remsima Delivers Positive Results in IBD Switching Study

October 4th 2021

By Tony Hagen

Studies of the infliximab biosimilar Remsima in patients with inflammatory bowel disease were presented at United European Gastroenterology Week 2021.

Amgen Estimates $9.8 Billion in Cumulative US Biosimilar Savings

September 22nd 2021

By Tony Hagen

In a biosimilar trend report, Amgen discusses marketing achievements, US biosimilar policy, payer and provider acceptance of these agents, and the outlook for further growth.